Intracellular cAMP levels are regulated by cAMP synthesis and degradation rate. Nine isoforms of cAMP-synthesizing enzymes called adenylyl-cyclases (ACs) and eleven phosphodiesterases (PDEs) that degrade cyclic nucleotides have been identified. Both types of enzymes exhibit variations not only in their expression pattern distribution throughout the brain, but also in their regulatory characteristics. Different isoforms of ACs and PDEs may be co-expressed in a single cell, thus a gradient of cAMP intracellular levels is formed, which accounts for the diversity of cell responses. Among these isoforms, AC5 and PDE7B are highly expressed in striatum, where the cAMP pathway is implicated in diverse behavioural functions. Striatal AC5 is involved in drug reinforcing actions and motor activity. Less is known about the role of the PDE7B isoenzyme. We performed a double in situ hybridization analysis of the co-expression patterns of AC5 and PDE7B with µ-opioid-receptor, D1-and D2-receptor mRNAs to contribute to a better understanding in the regulation of cAMP levels under dopamine or opioidergic pathway activation in striatum. We found co-expression of AC5 and PDE7B mRNAs in caudate-putamen and nucleus accumbens; we also encountered that more than 50% of MOR, D2-and D1-expressing cells contained AC5 and PDE7B mRNAs. The presence of AC5 and PDE7B mRNAs in D1-and D2-containing cells suggests the participation of these enzymes in striatal functions involving dopaminergic pathways. Co-localization of both isoenzyme mRNAs with MOR expressing cells suggests their involvement in opioid reinforcing effects.
(AC1, AC5, AC8, AC9), being AC5 the most abundant in that brain region (Glatt et al. 1993 , Matsuoka et al. 1997 . AC5 is involved in almost all the known functions regulated by the striatum: its expression is important although not essential for morphine effects after μ-opioid receptor (MOR) activation, which supports its role in drug-preference behaviour (Kim et al. 2006) . Besides, AC5 has been proposed as the key AC activity of striatum for the dopamine effects on locomotion induced by D2 receptor agonists, but not by those of D1 (Lee et al. 2002) . In ventral striatum (nucleus accumbens), AC5 has been implicated in the anxiety behaviour displayed by animals as a response to stressful stimuli (Kim et al. 2008) . Efforts have been made to involve AC5 in behaviours controlled by striatum in studies performed with AC5 -/-KO animals, to assay its main role in the locomotion produced by drug addiction. However, it is also possible that the enhancement of other AC activities, that exert a compensatory effect due to the lack of AC5 expression in those cells enhances PDE7B expression (Sasaki et al. 2004) . Among the phosphodiesterases expressed in striatum, PDE7B is the single-substrate degrading PDE with the highest affinity for cAMP; thus, it could be regulating cyclic nucleotide levels at basal conditions (Menniti et al. 2006 ).
Striatal cells have a differential localization and expression of PDEs. In fact, the participation of these enzymes in motor and cognitive functions might be due to the specific PDE involved. Since the use of PDE7B specific inhibitors has not yet been possible, the identification of PDE7B sub-cellular distribution in striatum by the analysis of the phenotype of its expressing-cells (and its proportion in every cell population) could help to understand regulatory processes involved and to identify the controlling factors associated with PDE activities and expression. It would also contribute to the design of specific pharmacological agents for the treatment of different disorders, minimizing secondary effects of PDE inhibition.
Despite the high striatal expression levels of AC5 and PDE7B, co-localization studies of their mRNAs with MOR and dopamine receptors are lacking. Therefore, the aim of this study is to analyze the cellular phenotype of AC5 and PDE7B expressing-cells in striatum by double in situ hybridization histochemistry for both enzyme mRNA expressions, to obtain information on the co-localization of the above mentioned neurotransmitter receptors with these particular enzymes, as well as their potential participation in different basal ganglia functions and the possible regulatory characteristics of the cAMP pathways in which AC5 and PDE7B might be participating.
Results.
Using double in situ hybridization histochemistry, we performed co-localization analysis of mRNAs coding for different neurotransmitter receptors (NTRs) viz., MOR (Fig 1A) , D1 ( Fig   1D) , and D2 ( Fig 1G) , with those of cAMP level-regulating enzymes particularly enriched in striatum, such as phosphodiesterase type 7B (PDE7B) (Fig 1J) (Reyes-Irisarri et al. 2005) and adenylcyclase type 5 (AC5) (Fig 1K) (Sanabra and Mengod, unpublished data and (Matsuoka et al. 1997) ).
Autoradiographic signals showed specific hybridization patterns for μ-opioid, D1 and D2, receptors and PDE7B in striatum, as it has been described elsewhere (Mansour et al. 1994 , Mengod et al. 1989 , Mengod et al. 1991 , Reyes-Irisarri et al. 2005 (Fig 1A, D , G, J), supporting the selectivity of the probes used.
MOR signal was predominant in the dorsal part of striatum ( Fig 1A) ; several MOR Regarding AC5 or PDE7B positive cells as 100%, the extent of neurons co-expressing AC5/D1 and PDE7B/D1 was the highest (59, and 58% respectively) and similar to the percentage of AC5/MOR and PDE7B/MOR neurons, supporting the expression of these four mRNAs in a high proportion in striatal neurons. AC5/D2 and PDE7B/D2 cells were present in a lower extent (Table 3) .
Discussion.
Regulation of cAMP levels plays a key role for striatum-controlled functions such as movement behaviour and drug reinforcement effects. Opioid or ethanol repeated administration enhances cAMP, CREB and PKA levels and phosphorylated factors as targets for CREB (Koob 1992 . These increased cAMP levels have been related to behavioural changes induced by drugs, such as aversive state of animals during drug withdrawal (Nestler et al. 1997) , as well as drug tolerance, dependence and reward mechanisms.
Locomotion is another behaviour altered by drugs (Barrot et al. 2002 ) and regulated by striatal pathways. This process includes D1 receptor activation by psychostimulant administration, as well as increased cAMP levels in striatum. Thus, enzymes regulating cAMP levels in the striatum are highly important given the variety of drug mechanisms and neurodegenerative processes that depend on dopamine effects for the tuning of cyclic nucleotide content. Among those cAMP synthesizing enzymes expressed in striatum, AC5 is the most abundant. Efforts have been made to relate the activity of this enzyme to striatum-controlled functions, as well as to different behaviours triggered by D1-and D2-receptor activation (Kim et al. 2008 , Kim et al. 2006 , Lee et al. 2002 .
Dopamine released in the striatum acts on medium spiny neurons containing D1 and D2 receptors, to produce an integrated behavioural response of animals to dopamine tone. D2 agonist administration in striatum is able to reduce increased AC activity provoked by D1-stimulation. The importance of AC5 for the balance of these two D1 and D2 regulated pathways in the control of locomotion is evidenced in studies with AC5 -/-KO mice, in which the D2-G αi -AC system is dependent on AC5 activity to trigger the behavioural response induced by dopamine agonists; in contrast, for D1 receptors, AC5 seems to be important, but the locomotion displayed by animals also needs of other non AC5 factors (Lee et al.
2002).
Besides the dopamine system, the opioidergic pathway is relevant to drug tolerance and dependence, as well as to reward processes of addiction controlled by striatum (Koob 1992) . Dopamine release in striatum affects the opioidergic system directly and induces the characteristic behaviours of drug addiction. AC5 activity has also been involved in the locomotion activation due to morphine administration. In AC5 -/-KO mice, morphine and MOR agonists induce a slighter decrease in striatal AC activity after forskolin administration and weaker, though not blocked effects on locomotion and drug preference than wild type animals (Kim et al. 2006 ). This suggests that AC5 is important but not essential for MOR activation.
In this study, we analyzed whether D1, D2 and MOR receptors are co-expressed with AC5, a cAMP-synthesizing enzyme, and PDE7B, a degrading one. We were also interested in the proportion of striatal receptor-containing cells expressing AC5 and PDE7B mRNAs. By understanding the regulatory characteristics of each enzyme and its predominance in specific striatal cells, our results could provide further insight into cAMPpathway regulation in striatum as the key to the diverse behavioural functions controlled by this region. It could also help in the determination of the potential role of AC5 and PDE7B activities in drug-related locomotion and reward mechanisms. Furthermore, it could enable the design of specific inhibitors of these enzymes as therapeutic agents to pathologies related to impaired processes controlled by striatum.
Our results showing more than 50% of MOR positive cells co-expressing AC5 mRNA are in agreement with previous studies that suggest AC5 as the main AC activity involved in morphine behavioural changes through MORs (Kim et al. 2006) . Other enzymes such as AC1, AC8 or AC9, also expressed in striatum, may account for residual behavioral effects and AC activity of AC5 -/-KO animals after morphine administration (Kim et al. 2006 ). This evidence indicates that each enzyme regulates cAMP levels in a stimulus-specific manner.
A high percentage of D1 expressing cells exhibited AC5 mRNA. Given that more caudateputamen neurons co-expressed D1/AC5 than MOR/AC5 mRNAs (80 vs 64%), it is possible that some D1-mRNA-containing cells express simultaneously AC5 and MOR receptors (McGinty et al. 1998 ).
We observed co-localization of AC5 with D2 mRNAs; this finding suggests a role for D2
agonists in locomotion, after DA agonist administration through AC5 activation identified in AC5 -/-KO animals (Lee et al. 2002) . Given the higher percentage of D2/AC5 containing cells than that of MOR/AC5, it is likely that D2/AC5 mRNAs-containing cells are also expressing MORs. This hypothesis could explain the blocked opioid effect on locomotion after morphine administration in AC5 -/-KO animals (Lee et al. 2002) .
The presence of AC5 in both types of medium spiny neurons may account for the D1 and In nucleus accumbens we found co-localization of AC5 mRNA with D1 and D2 containing cells. In the mesolimbic pathway, dopamine signaling through D1 receptors increases cAMP levels, when animals are subjected to stressful conditions. Furthermore, activation of the cAMP pathway has been associated with the anxiety behavior displayed by these animals. Since AC5 -/-KO mice have an anxiolytic phenotype and higher locomotor and exploring activities; AC5 seems to be the main enzyme implicated in this behaviour. Our PDE7B is a cAMP degrading enzyme markedly expressed in the striatum with a high degree of specificity for its substrate. Its distribution in medium spiny neurons has been analyzed (Reyes-Irisarri et al. 2005) , but the phenotype of the PDE7B containing cells has not been identified. We found here that PDE7B mRNA co-localizes with both D2 and D1
containing neurons in striatum and nucleus accumbens. Since PDE7B mRNA levels are enhanced after D1 agonist administration (Sasaki et al. 2004) , it seems that PDE7B activity may return cAMP to basal levels after its increase due to an enhanced AC activity with an autorreceptor function. Thus, PDE7B mRNA could be a marker for D2 striatopallidal neurons. Although the former results suggest the non participation of PDE7B in DA release control, it is possible that its activity is involved in DA synthesis and release through the feedback loop of the MSN to SN and VTA, when the dopaminergic tone is increased in striatum.
The low Km of PDE7B for cAMP levels suggests its importance in maintaining cAMP levels in basal conditions, which is relevant for the tonic activation of D2-containing neurons. PDE7B expression in both D1-and D2-expressing striatal neurons suggests its participation in the integrated response of locomotion that depends on the activation of both types of cells.
In this respect, co-localization of PDE7B with D2 containing cells suggests that PDE7B specific inhibitors may exert antipsychotic actions and modulate hyperlocomotion induced by psychostimulants, since inhibiting PDE7B could enhance cAMP levels and counteract D2 receptor activation, as has been proved for other PDEs expressed in striatum, such as PDE10A (Weber et al. 2009 ). Also, since PDE7B is constitutively expressed, its activity may account for the tonic activity of the D2-expressing cells in the striatum. However, PDE7B has cAMP as unique substrate in contrast to other phosphodiesterases localized also in striatum, such as PDE10A (this enzyme also degrades cGMP). This characteristic is relevant for the potential counteracting effects of PDE7B inhibitors on D2 activation as therapy for psychosis.
Dopamine has been involved in striatal cell differentiation in rat embryonic cultures through D1 receptor activation (Schmidt et al. 1998 ); since PDE7B is co-localized with D1
receptors and D1 agonists increase PDE7B expression, it is not unlikely its participation in that cellular process.
Its co-localization with these DA receptors in nucleus accumbens and at the same time with AC5 mRNA, points towards PDE7B as a target for the control of anxiety behaviours involving AC5 activation. Also, since low cAMP levels in nucleus accumbens have been related to the pre-pulse deficiency (PPI) of the startle reaction (Weber et al. 2009 ), which is considered a behavioural characteristic of schizophrenia appearing in postpartum rats, PDE7B may be a target for the control of this mental illness (Byrnes et al. 2007 ).
It would be helpful to develop PDE7B inhibitors, since those available that target other PDE activities induce some side effects such as emesis and cardiotoxicity (Barnes et al.
2001).
The presence of PDE7B mRNA in MOR, D1 and D2 expressing cells, together with the observation that all AC5-expressing cells also contain PDE7B mRNA, suggests that all MOR, D1 and D2 positive cells containing AC5 mRNA simultaneously express PDE7B.
Thus, PDE7B activity may induce compensating increments of cAMP levels and prepare neurons for a subsequent stimulus after D1 activation. In addition, its constitutive expression (Sasaki et al. 2004 ) PDE7B may contribute to maintain low cAMP levels in MOR expressing cells, as well as may be in part responsible for the locomotor activation and drug preference induced by morphine.
Its co-localization with MOR in nucleus accumbens indicates that regulation of PDE7B activity may be important for therapy (control) of drug addiction, since increased cAMP levels has been associated with the negative motivational state during drug withdrawal.
The observation of cells co-expressing AC5 and PDE7B enzymes may help to identify their roles as regulating enzymes of cAMP content and their participation in specific striatal functions. Their co-expression in both dorsal striatum and nucleus accumbens suggests that these enzymes may be controlling cAMP levels and in turn CREB phosphorylation among other functions, as well as transcription of opioid peptide genes that are expressed in both striato-nigral (dynorphin) and striato-pallidal (proenkephalin) cells, which participate in long-term neural and behavioral plasticity in response to drugs. Also, the co-expression of PDE7B and AC5 indicates their possible participation in drug reinforcement mechanisms controlled by VTA neurons, by the activation of the VTA or SN firing rate within the long-loop feedback that includes direct and indirect pathways.
Experimental Procedure.
Tissue preparation
Male Wistar rats averaging 250g in body weight (n=4) were kept in an animal house under controlled light and temperature conditions until they were sacrificed by decapitation.
tetrazolium and 1.65 mg bromochloroindolyl phosphate (Roche Diagnostics GmbH) diluted in 10 ml of alkaline buffer. The enzymatic reaction was blocked by extensive rinsing in the alkaline buffer containing 1 mM EDTA. Sections were then briefly dipped in 70% and 100% ethanol, air-dried, dipped in cholodion and then into Ilford K5 nuclear emulsion (Ilford, Mobberly, Chesire, UK) diluted 1:1 with distilled water. They were exposed in the dark at 4ºC for two weeks for the double-labeled experiment of AC5/PDE7B, and for 4 weeks for the rest of the experiments, and finally developed in Kodak D19 (Kodak, Rochester, NY, USA) for 5 min, and fixed in Ilford Hypam fixer (Ilford). For film autoradiography, hybridized sections were exposed to Biomax-MR (Kodak) films for 3 days at -70ºC.
Several routine controls were carried out to determine the specificity of the hybridization signals. As we have previously described (Pompeiano et al. 1992 We analyzed 5 fields/side of each dorsal striatum (ten fields/section). Since we had three different locations (at coordinates of 1.7, 1 and -0.8mm) (Paxinos G, Watson C. 1998) sections/location, we examined a total of 60 fields/dorsal striatum/rat. Given that only two locations contained the nucleus accumbens, the total number of fields for this region was 40 fields/rat. Dorsal striatum located at 1.7 and 1.0 mm was counted above an imaginary line drawn at 6 mm of vertical (V) coordinates (at the level of the base of the lateral ventricle) and below the corpus callosum which is easily recognizable. At the location 1.7 mm, the positive cells of the nucleus accumbens were counted below the line mentioned (V 6 mm), lower limit at V 7.8, left lateral limit at 0.5 (or -0.5 for the left section), and right limit at 2.8 mm, being careful to examine only the area nearest to the anterior commissure.
For the section at 1.00 mm, nucleus accumbens positive cells were counted inside the limits of an imaginary square figure: left limit L 0.8 mm (or -0.8 mm for the left side of the section), right limit 2.7 mm (or -2.7 mm), upper limit V 6.9 mm and lower limit V 7.8 mm.
The section at -0.8 mm contained no nucleus accumbens; thus, dorsal striatum was exclusively examined. We calculated the percentage of NTR-containing cells expressing AC5 or PDE7B (NTR cells were taken as 100%) and the percentage of AC5-expressing cells containing also PDE7B mRNA (AC5 positive cells were considered as 100%) in dorsal and ventral striatum. Also, we made a calculus of the extent of AC5 or PDE7B-expressing cells (each one taken as 100%) that contained NTR mRNA in caudateputamen and nucleus accumbens.
Preparation of the figures.
Hybridized tissue section images from film autoradiograms were taken with a Wild 420
Leica macroscope equipped with a digital camera (DXM1200 F, Nikon) and ACT-1 Nikon Software. Microphotographies of the hybridized tissue slides were performed using a Zeiss axioplan microscope equipped with a digital camera (DXM1200 F, Nikon) and ACT- 
